Recent Advances of Regenerative Medicine
Biorefinery
Micro/Nano-biotechnology
Medical Devices
Vaccine
Smart Drug Delivery Strategy
Regulatory and GMP Compliance
Business Development
Technology Licensing
Therapeutic Antibody
Botanical New Drug Development
Clinical Drug Development
Ubiquitous Healthcare
Session 1. Special Speech

This is to show the strategy of an exemplary research-based global leading pharmaceutical company in successful business development by collaboration and partnerships with smaller companies with innovative technologies.
Chair : Kyu Chan KIM, Science Ambassador, Merck & Co., Inc.
- Merck's Partnering Strategy in the Asia-Pacific Region
Greg WIEDERRECHT, VP/Head, External Scientific Affairs, Worldwide Licensing & External Research, Merck & Co., Inc.
Session 2. Benchmarking Globally Commercialized Innovative Therapeutics & Technologies

For successful global commercialization, primary and most important element should be technological excellence and innovation, which could be secured only from years of focused refinement and innovative challenges.
Chair : Kyu Chan KIM, Science Ambassador, Merck & Co., Inc.
- Success Elements in R&D Strategies for Competitive Therapeutics
  : Hybrid R&D
Sung Chun KIM, CTO, LG Life Sciences Ltd.
- Maximizing Value Through Business Development-
  : Worldwide and Regional Strategies
Douglas E. ONSI, Partner, HealthCare Ventures
- CrystalGenomics’s Competitiveness in Drug Discovery
  : Structural Chemoproteomics-based Drug Discovery
Joong Myung CHO, President/CEO, CrystalGenomics, lnc.
Session 3. Solutions to Complicated Dilemmas of Funding-investment Opportunities & Business Development

Realization of technologies in commercial use needs financial instruments. Experienced capitalists explain how and why venture capitals decide where to invest the funds in this high risk, high return industry.

Chair : Byung Hwan RYU, CEO, Seoul Pharma Co., Ltd.
- VCs’ Perspective of What Emerging Companies Should Be Doing
Hui-Hsing MA, Venture Partner, Life Sciences, TVM Capital
- Novartis Strategy of Global Funding in the Drug Discovery
Reinhard J. AMBROS, Executive Director/Head, Novartis Venture Funds, Novartis International
- Recent Trends and Strategies for Biopharmaceutical Financing in the
  Current Capital Market
H. Michael KEYOUNG, Director, Private Equity-Venture Capital Group, Burrill & Company
Session 4. Technological Innovation Strategy for Biotechnology

Market readiness and commercial acumen should be well wrapped up in addition to technological excellence, for successful licensing deals.

Chair : Sung Chun KIM, CTO, LG Life Sciences Ltd.
- Integration of Expertise, Research and Partnering
  : Winning Strategy
Sung-eun YOO, Director, The Center for Biological Modulators, Korea Research Institute of Chemical Tech.
- Harnessing Korean Biotech for the Markets
  : The Importance of IP Protection & Technology Transfer
Lawrence A. KOGAN, President/CEO, Institute for Trade, Standards & Sustainable Development Inc.